Royal Bank of Canada Analysts Give Teva Pharmaceutical Industries (TEVA) a $13.00 Price Target
Several other analysts have also recently issued reports on TEVA. Piper Jaffray Companies set a $16.00 target price on Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Thursday. BTIG Research raised their price target on Teva Pharmaceutical Industries to $20.00 in a report on Friday. Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the company a hold rating in a report on Thursday. Guggenheim assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 12th. They set a neutral rating and a $16.00 price target for the company. Finally, Oppenheimer restated a hold rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $20.65.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $18.61 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $38.31. The stock has a market capitalization of $18,907.76, a PE ratio of 4.30 and a beta of 0.55.
Several large investors have recently bought and sold shares of the company. Fieldpoint Private Securities LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $171,000. Arthur Zaske & Associates LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $372,000. Sterling Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $263,000. Point72 Asset Management L.P. bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $2,200,000. Finally, Chevy Chase Trust Holdings Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 81.5% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after purchasing an additional 5,497 shares during the last quarter. 52.05% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Royal Bank of Canada Analysts Give Teva Pharmaceutical Industries (TEVA) a $13.00 Price Target” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/royal-bank-of-canada-analysts-give-teva-pharmaceutical-industries-teva-a-13-00-price-target/1770436.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.